Treatment of ccRCC cells with the GLI1-specific inhibitor, GANT58, significantly inhibited cell proliferation (Fig. 5B) and OCT4 and Nanog mRNA expressions (Fig. 5C). This evidence concerns the gene NANOG and nonpapillary renal cell carcinoma.